Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a newer class of glucose-lowering drugs, have emerged as promising candidates for mitigating diabetes-associated cognitive decline (12, 13). This evidence concerns the gene SLC5A2 and Mental deterioration.